➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Dow
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,994,615

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,994,615
Title:Self-regulated peptide hydrogel for insulin delivery
Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients\' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
Inventor(s): Langer; Robert S. (Newton, MA), Anderson; Daniel G. (Sudbiry, MA), Gu; Zhen (Cambridge, MA), Aimetti; Alex Arthur (Waltham, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA)
Application Number:14/379,477
Patent Claims:1. Self-assembling glucose binding peptides comprising (a) a hydrophilic region comprising a charged segment which enhances solubility of the self-assembling peptide in an aqueous environment, (b) a hydrophobic region, (c) a beta-sheet forming region, and (d) an organic borate glucose binding moiety, wherein the hydrophilic and hydrophobic regions, present in distinct regions, sequentially along the backbone of the self-assembling peptide, are covalently linked via the beta-sheet forming region, wherein the self-assembling peptides are between six and about 200 .alpha.-amino acid residues, wherein the self-assembling peptides self-assemble under physiological conditions, of pH of approximately 7-7.5, to form a hydrogel, and wherein binding of glucose to the glucose binding moiety increases the permeability of the hydrogel.

2. The self-assembling glucose binding peptides of claim 1, wherein the hydrophilic region comprises charged amino acid residues.

3. The self-assembling glucose binding peptides of claim 1, wherein the hydrophobic region comprises side chains or amino acids forming a beta sheet structure.

4. The self-assembling glucose binding peptides of claim 1, wherein the organic borate is a phenyl borate.

5. The self-assembling glucose binding peptides of claim 1, wherein the glucose binding moiety is attached to the hydrophobic region.

6. The self-assembling glucose binding peptides of claim 1, wherein the beta-sheet forming regions of individual self-assembling peptides associate to form nanofibers.

7. The self-assembling glucose binding peptides of claim 1, wherein the beta-sheet forming region has about four to ten amino acid residues.

8. The self-assembling glucose binding peptides of claim 7, wherein the hydrophilic region has about two to seven amino acid residues.

9. The self-assembling glucose binding peptides of claim 8, the self-assembling peptide comprising between eight and about twenty-four .alpha.-amino acid residues.

10. A self-assembling glucose binding peptide having the chemical structure: ##STR00001##

11. A hydrogel composition for delivering insulin or an insulin analog, comprising Insulin or an insulin analog; and self-assembling peptides comprising (a) a hydrophilic region comprising a charged segment which enhances solubility of the self-assembling peptide in an aqueous environment, (b) a hydrophobic region, (c) a beta-sheet forming region, (d) an organic borate glucose binding moiety, wherein the hydrophilic and hydrophobic regions, present in distinct regions, sequentially along the backbone of the self-assembling peptide, are covalently linked via the beta-sheet forming region, wherein the self-assembling peptides are between six and about 200 .alpha.-amino acid residues and wherein the self-assembling peptides self-assemble under physiological conditions, of pH of approximately 7-7.5, forming a hydrogel, wherein binding of glucose to the glucose binding moiety increases the permeability of the hydrogel, and wherein the insulin or insulin analog is released.

12. The composition of claim 11, wherein the composition comprises insulin.

13. The composition of claim 11, wherein the insulin is selected from the group consisting of insulin lispro, insulin glulisine, insulin aspart, and insulin detemir.

14. The composition of claim 11, wherein the permeability of the hydrogel to insulin is increased when tissue glucose levels at physiological pH are increased.

15. The composition of claim 11, wherein the insulin or insulin analog is entrapped within the hydrogel.

16. A method for making a formulation for delivering insulin comprising self-assembling glucose binding peptides, wherein the self-assembling peptides each comprise: (a) a hydrophilic region comprising a charged segment which enhances solubility of the self-assembling peptide in an aqueous environment, (b) a hydrophobic region, (c) a beta-sheet forming region, and (d) an organic borate glucose binding moiety, wherein the hydrophilic and hydrophobic regions, present in distinct regions, sequentially along the backbone of the self-assembling peptide, are covalently linked via the beta-sheet forming region, wherein the self-assembling peptide comprises between six and about 200 .alpha.-amino acid residues, and wherein the self-assembling peptides self-assemble under physiological conditions, of pH of approximately 7-7.5, to form a hydrogel, and wherein binding of glucose to the glucose binding moiety increases the permeability of the hydrogel, comprising adding insulin or insulin analog to a solution of the self-assembling peptides and adding ions or changing pH to cause the self-assembling peptides to form a hydrogel entrapping the insulin or insulin analog in the hydrogel.

17. The method of claim 16, wherein the hydrophilic region has about two to seven amino acid residues.

18. The method of claim 17, the self-assembling peptide comprising between eight and about twenty-four .alpha.-amino acid residues.

19. A method of alleviating one or more symptoms of diabetes comprising administering to a diabetic individual an effective amount of the formulation of claim 11.

20. The method of claim 19 wherein the formulation is administered by subcutaneous injection.

21. The method of claim 16, wherein the insulin or insulin analog is entrapped within the hydrogel.

22. The method of claim 16, wherein the beta-sheet forming regions of individual self-assembling peptides associate to form nanofibers.

Summary for Patent:   Start Trial

PCT Information
PCT FiledFebruary 19, 2013PCT Application Number:PCT/US2013/026632
PCT Publication Date:August 22, 2013PCT Publication Number:WO2013/123491

Details for Patent 9,994,615

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk LEVEMIR insulin detemir INJECTABLE; INJECTION 021878 001 2005-10-19   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
Novo FIASP insulin aspart SOLUTION;INTRAVENOUS, SUBCUTANEOUS 208751 001 2018-03-06   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
Novo FIASP FLEXTOUCH insulin aspart SOLUTION;SUBCUTANEOUS 208751 002 2018-03-06   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
Novo FIASP PENFILL insulin aspart SOLUTION;SUBCUTANEOUS 208751 003 2018-03-06   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Dow
Boehringer Ingelheim
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.